日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

MK-7602: a potent multi-stage dual-targeting antimalarial

MK-7602:一种强效的多阶段双靶点抗疟药

Favuzza, Paola; Palandri, Josephine; de Lera Ruiz, Manuel; Bailey, Wendy; Boyce, Christopher W; Danziger, Andrew; Fawaz, Maria V; Kelly, Michael; Murgolo, Nicholas; Robbins, Jonathan A; Vavrek, Marissa; Zhao, Lianyun; Lei, Zhiyu; Guo, Zhuyan; Reaksudsan, Kitsanapong; Steel, Ryan W J; Hodder, Anthony N; Ngo, Anna; Dziekan, Jerzy M; Thompson, Jennifer K; Triglia, Tony; Birkinshaw, Richard W; Penington, Jocelyn Sietsma; Scally, Stephen W; Dans, Madeline G; Coyle, Rachael; Sevilleno, Nicole; Orban, Agnes; Feufack-Donfack, Lionel Brice; Popovici, Jean; Lee, Marcus C S; Papenfuss, Anthony; Lowes, Kym N; Sleebs, Brad E; McCarthy, James S; McCauley, John A; Boddey, Justin A; Olsen, David B; Cowman, Alan F

First-in-human safety and pharmacokinetics of MK-7602, the antimalarial inhibitor of plasmepsins IX/X, in single- and multiple-ascending-dose studies

MK-7602(一种抗疟疾药物,可抑制疟原虫蛋白酶IX/X)的首次人体安全性和药代动力学研究(单次和多次递增剂量研究)

Stanley, Susan E; Carstens, Russ P; Liberti, Maria V; Eertmans, Ward; Vranckx, Myrthel; Longo, Diane; Ghosal, Nairita; Vavrek, Marissa; Olsen, David B; Cowman, Alan F; Reynders, Tom; Cilissen, Caroline; Laethem, Tine; Rottey, Sylvie; Robbins, Jonathan A; Stoch, S Aubrey; Nussbaum, Jesse

Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.

MK-6194(一种旨在选择性激活调节性 T 细胞的 IL-2 突变体)的安全性、药代动力学和药效学:单次递增剂量和多次递增剂量试验数据

Scheid Johannes F, Cunningham-Bussel Kiki, Kim Nancy, Agarwal Shiuli, Nieddu Garrett, Cote Josee, Lemoine Lieselotte, Decaesteker Tatjana, Mendez Luis, Paul Erina, Love-Gregory Latisha, Contreras Alejandra Virginia, Zhao Xuemei, Franco-Dilone Lucia, Pang Ling, Baltus Gretchen A, Beaumont Maribel, Shah Ketal, Higginson-Scott Nathan, Kis-Toth Katalin, Otipoby Kevin L, Viney Joanne L, Sicard Eric, Rottey Sylvie, Sundy John S, Van Dyck Kristien, Laethem Tine, Larson Patrick, Sutradhar Santosh, Wnek Richard, Bueters Tjerk, Lai Eseng, Stoch S Aubrey, Iwamoto Marian, Robbins Jonathan A

Gefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trial

吉法匹坦作为P2X3受体拮抗剂治疗阻塞性睡眠呼吸暂停:一项随机对照试验

Robbins, Jonathan A; Sands, Scott; Maganti, Lata; Crumley, Tami; Fox-Bosetti, Sabrina; Hussain, Azher; Schwartz, Howard; Safirstein, Beth; Ahmad, Maha; Dragone, Leonard; Nussbaum, Jesse; Kushida, Clete; Iwamoto, Marian; Stoch, S Aubrey

Requirements and reasons for effective inhibition of the anaphase promoting complex activator CDH1

有效抑制后期促进复合物激活因子 CDH1 的要求和原因

Robbins, Jonathan A; Cross, Frederick R